Tilarginine
Tilarginine is a small molecule pharmaceutical. It is currently being investigated in clinical studies. It is known to target nitric oxide synthase, inducible, nitric oxide synthase, endothelial, and nitric oxide synthase, brain.
Download report
Favorite
Commercial
Therapeutic Areas
No data
Trade Name
FDA
EMA
No data
Drug Products
FDA
EMA
New Drug Application (NDA)
New Drug Application (NDA)
Abbreviated New Drug Application (ANDA)
Abbreviated New Drug Application (ANDA)
No data
Labels
FDA
EMA
No data
Indications
FDA
EMA
No data
Agency Specific
FDA
EMA
No data
Patent Expiration
No data
ATC Codes
No data
HCPCS
No data
Clinical
Clinical Trials
51 clinical trials
View more details
Mock data
Subscribe for the real data
Subscribe for the real data
Indications Phases 4
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Healthy volunteers/patients | — | 3 | 1 | — | 1 | 4 | 9 | ||
| Obesity | D009765 | EFO_0001073 | E66.9 | 2 | — | — | 1 | 1 | 4 |
| Type 2 diabetes mellitus | D003924 | EFO_0001360 | E11 | — | 1 | — | 1 | — | 2 |
| Obstructive sleep apnea | D020181 | EFO_0003918 | G47.33 | — | — | — | 1 | — | 1 |
Indications Phases 3
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Hyperlipidemias | D006949 | EFO_0003774 | E78.5 | — | 2 | 1 | — | — | 2 |
| Cardiogenic shock | D012770 | R57.0 | — | — | 1 | — | — | 1 |
Indications Phases 2
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Sickle cell anemia | D000755 | EFO_0000697 | D57 | 2 | 2 | — | — | — | 4 |
| Regional blood flow | D012039 | 1 | 2 | — | — | — | 3 | ||
| Ocular physiological phenomena | D009799 | 1 | 2 | — | — | — | 3 | ||
| Triple negative breast neoplasms | D064726 | 1 | 2 | — | — | — | 2 | ||
| Cardiovascular diseases | D002318 | EFO_0000319 | I98 | — | 1 | — | — | 1 | 2 |
| Anemia | D000740 | EFO_0004272 | D64.9 | — | 1 | — | — | — | 1 |
| Breast neoplasms | D001943 | EFO_0003869 | C50 | — | 1 | — | — | — | 1 |
Indications Phases 1
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Hypertension | D006973 | EFO_0000537 | I10 | 3 | — | — | — | 1 | 4 |
| Heart failure | D006333 | EFO_0003144 | I50 | 2 | — | — | — | — | 2 |
| Postural orthostatic tachycardia syndrome | D054972 | G90.A | 2 | — | — | — | — | 2 | |
| Liver cirrhosis | D008103 | EFO_0001422 | K74.0 | 2 | — | — | — | — | 2 |
| Chronic obstructive pulmonary disease | D029424 | EFO_0000341 | J44.9 | 1 | — | — | — | — | 1 |
| Pulmonary arterial hypertension | D000081029 | 1 | — | — | — | — | 1 | ||
| Cerebral arterial diseases | D002539 | EFO_1000859 | 1 | — | — | — | — | 1 | |
| Non-small-cell lung carcinoma | D002289 | 1 | — | — | — | — | 1 | ||
| Hodgkin disease | D006689 | C81 | 1 | — | — | — | — | 1 | |
| Squamous cell carcinoma of head and neck | D000077195 | 1 | — | — | — | — | 1 |
Show 13 more
Indications Without Phase
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Glomerular filtration rate | D005919 | EFO_0005208 | — | — | — | — | 1 | 1 | |
| Renal circulation | D012079 | — | — | — | — | 1 | 1 | ||
| Renal plasma flow | D017595 | — | — | — | — | 1 | 1 | ||
| Type 1 diabetes mellitus | D003922 | EFO_0001359 | E10 | — | — | — | — | 1 | 1 |
| Macular degeneration | D008268 | EFO_0001365 | H35.30 | — | — | — | — | 1 | 1 |
| Hyperemia | D006940 | EFO_0003822 | H34.82 | — | — | — | — | 1 | 1 |
| Raynaud disease | D011928 | EFO_1001145 | I73.0 | — | — | — | — | 1 | 1 |
| Cold temperature | D003080 | — | — | — | — | 1 | 1 | ||
| Pure autonomic failure | D054970 | — | — | — | — | 1 | 1 | ||
| Aging | D000375 | GO_0007568 | R41.81 | — | — | — | — | 1 | 1 |
Show 2 more
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
| Drug common name | TILARGININE |
| INN | tilarginine |
| Description | N-Methylarginine is an inhibitor of nitric oxide synthase. Chemically, it is a methyl derivative of the amino acid arginine. It is used as a biochemical tool in the study of physiological role of nitric oxide.
|
| Classification | Small molecule |
| Drug class | — |
| Image (chem structure or protein) | |
| Structure (InChI/SMILES or Protein Sequence) | CNC(=N)NCCC[C@H](N)C(=O)O |
Identifiers
| PDB | — |
| CAS-ID | 17035-90-4 |
| RxCUI | — |
| ChEMBL ID | CHEMBL256147 |
| ChEBI ID | 28229 |
| PubChem CID | 4366 |
| DrugBank | — |
| UNII ID | 27JT06E6GR (ChemIDplus, GSRS) |
Target
Agency Approved
No data
Alternate
NOS2
NOS2
NOS3
NOS3
NOS1
NOS1
Organism
Homo sapiens
Gene name
NOS2
Gene synonyms
NOS2A
NCBI Gene ID
Protein name
nitric oxide synthase, inducible
Protein synonyms
HEP-NOS, Hepatocyte NOS, Inducible NO synthase, Inducible NOS, iNOS, nitric oxide synthase 2, inducible, nitric oxide synthase 2A (inducible, hepatocytes), nitric oxide synthase, macrophage, NOS type II, NOS, type II, Peptidyl-cysteine S-nitrosylase NOS2
Uniprot ID
Mouse ortholog
Nos2 (18126)
nitric oxide synthase, inducible (P29477)
Variants
Clinical Variant
No data
Financial
No data
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Mock data
Subscribe for the real data
Subscribe for the real data
Additional graphs summarizing 86 documents
View more details
Safety
Black-box Warning
No Black-box warning
Adverse Events
Top Adverse Reactions
0 adverse events reported
View more details
Premium feature
Learn more about premium features at pharmakb.com
Learn more